Nuedexta to treat PBA
“PREVENTION IS CHEAPER THAN TREATMENT” Give Your body the best– NUTRITION of 17 Whole Fruits & Vegetables with 2 grains and the sugar, salt and water taken out (NO GLUTEN & in a CAPSULE, CHEWABLE or POWERED DRINK) It is Easier and Cheaper to Prevent an Illness (Disease) than to Try and Deal with it when it Occurs. We are ALL OVER-FED and UNDER NOURISHED! When You Feel Good You Look Good !!! I want everyone Healthy and Happy and I have not used my cane, scooter or wheel chair in 9 years as of April 2, 2015.. Please go into my web site www.jpwobbles.com learning how Whole Food Nutrition is good for everyone.
Please contact me with any questions at 1-208-773-9372, cell phone 1-208-818-2150 or my e mail email@example.com
FDA Approves Nuedexta to treat Pseudobulbar Affect (PBA)
On October 29, 2010,Avanir Pharmaceuticals, Inc. announced the approval of Nuedexta™ by the Food and Drug Administration (FDA) for the treatment of pseudobulbar affect (PBA) associated with certain neurological conditions, including MS. PBA is characterized by uncontrolled, inappropriate, and/or exaggerated episodes of crying, laughing, or other emotional display. PBA occurs involuntarily with little or no stimulation to invoke such a response. It can greatly impact social situations and overall quality of life, both for the patient and his or her family.
Nuedexta is an oral drug in capsule form. Initially, a patient is given one capsule daily for the first seven days. Beginning on the eighth day, the medication is increased to the full dose of two capsules daily (one capsule every 12 hours). No one should take more than two capsules within a 24-hour period, and if a dose is missed, it will need to be skipped, as two doses should never be taken at the same time.
In studies with Nuedexta, episodes of excessive crying and laughing were significantly reduced in the treated group as compared to placebo, both in terms of frequency and severity. According to Avanir, the response to this drug is readily observable within a short time – often within the first week. In the most recent clinical trial (the STAR trial), about half of the patients with PBA experienced a complete remission of thissymptom by the end of the study while taking Nuedexta. Scores on a scale measuring emotional lability (the Center for Neurologic Study-Lability Scale [CNS-LS]) significantly decreased. The approval of Nuedexta comes after 10 years of research and development.
From: MSAA Motivator Winter/Summer 2011